Evidence map›Paper›PMID 40626562›Full record

ArticleNucleic acids research2025

A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin.

Viola Ellison, Alla Polotskaia, Gu Xiao, Pamella Leybengrub, Rusia Lee, Weigang Qiu, Ronald C Hendrickson, Wenwei Hu, Jill Bargonetti

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Viola EllisonDepartment of Biological Sciences, Hunter College City University of New York, Belfer Research Building, New York, NY 10021, United States.
Alla PolotskaiaDepartment of Biological Sciences, Hunter College City University of New York, Belfer Research Building, New York, NY 10021, United States.
Gu XiaoDepartment of Biological Sciences, Hunter College City University of New York, Belfer Research Building, New York, NY 10021, United States.
Pamella LeybengrubDepartment of Biological Sciences, Hunter College City University of New York, Belfer Research Building, New York, NY 10021, United States.
Rusia LeeDepartment of Biological Sciences, Hunter College City University of New York, Belfer Research Building, New York, NY 10021, United States.
Weigang QiuDepartment of Biological Sciences, Hunter College City University of New York, Belfer Research Building, New York, NY 10021, United States.
Ronald C HendricksonDepartment of Biochemistry and Molecular Biology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, United States.
Wenwei HuDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, United States.
Jill BargonettiDepartment of Biological Sciences, Hunter College City University of New York, Belfer Research Building, New York, NY 10021, United States.ORCID 0000-0003-2692-0991

Funding

TUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221704 · NCI · HUNTER COLLEGE · PI FRIDA E KLEIMAN · 2018 to 2026
$10.6M
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast CancerR01CA239603 · NCI · HUNTER COLLEGE · PI BARGONETTI, JILL E. · 2020 to 2024
$1.8M
NCI NIH HHS R01 CA239603NCI NIH HHS U54 CA221704NIH HHS R01CA239603NIH HHS U54 CA221704The Breast Cancer Research Foundation BCRF-20-011The Breast Cancer Research Foundation BCRF-21-011The Breast Cancer Research Foundation BCRF-22-011The Breast Cancer Research Foundation BCRF-23-011The Breast Cancer Research Foundation BCRF-24-011
6 · The paper itself

Abstract

DNA damage signaling requires functional interactions between 53BP1 and the wild-type p53 tumor suppressor. Cancer cells often express elevated levels of transcriptionally inactive mutant p53 (mtp53) that maintains MDM2 and MDMX (MDM4) binding partners. The ability of mtp53 to functionally interact with additional proteins in the context of a dynamic equilibrium with MDM2-MDMX heterodimers has not been described. Employing a stable isotope labeling in cell culture analysis in T47D breast cancer cells (expressing mtp53 L194F), we uncovered several chromatin-associated DNA replication and repair factors as MDM2-regulated phosphoproteins, including 53BP1. We used proximity ligation analysis in multiple breast cancer cell lines to confirm 53BP1-MDM2 complex formation. We demonstrated that a mtp53-MDM2/MDMX complex promoted 53BP1-MDC1 interactions by showing that mtp53-MDM2/MDMX complex disruptors, Nutlin 3a and ALRN-6924, reduced the 53BP1-MDC1 nuclear interactions (especially in S-phase). Surprisingly, these MDM2-driven MDC1-53BP1 interactions were not ATM dependent, suggesting distinct 53BP1-MDC1 complexes in response to genotoxic stress. We found that MDM2-deficient cells have increased poly-ADP-ribosylation on chromatin which supports the possibility that a mtp53-MDM2/MDMX pathway promotes aberrant DNA repair. Taken together, our data suggest that a mtp53-MDM2/MDMX complex orchestrates DNA repair machinery activity on chromatin, thus priming cancer cells for persistent DNA damage repair (CPR).

Indexed as

ChromatinDNA RepairIntracellular Signaling Peptides and ProteinsNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Trans-ActivatorsTumor Suppressor Protein p53Adaptor Proteins, Signal TransducingBreast NeoplasmsCell Cycle ProteinsCell Line, TumorFemaleHumansImidazolesMutationAdaptor Proteins, Signal TransducingCell Cycle ProteinsChromatinImidazolesIntracellular Signaling Peptides and ProteinsMDC1 protein, humanMDM2 protein, humanMDM4 protein, humanNuclear Proteinsnutlin 3PiperazinesProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2TP53BP1 protein, humanTP53 protein, humanTrans-ActivatorsTumor Suppressor p53-Binding Protein 1Tumor Suppressor Protein p53

Identifiers

PMID40626562
PMCPMC12235508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.